华蟾素胶囊联合XELOX方案治疗晚期胃癌的疗效及对患者免疫状态的影响
|
摘要
目的:探讨华蟾素胶囊联合奥沙利铂+卡倍他滨(XELOX方案)治疗晚期胃癌的疗效及对患者免疫状态的影响。方法:选取2016年1月至2018年2月江西省大余县人民医院收治的晚期胃癌患者50例,以随机数字表法分为观察组和对照组,每组25例。对照组患者给予XELOX方案治疗,观察组患者给予华蟾素胶囊联合XELOX方案治疗。比较两组患者的临床疗效、免疫功能及不良反应发生情况的差异。结果:观察组患者的近期总有效率为96.00%(24/25),明显高于对照组的76.00%(19/25),差异有统计学意义(P<0.05);治疗后,观察组患者CD_3~+、CD_4~+、CD_8~+及自然杀伤细胞水平明显高于对照组,差异均有统计学意义(P<0.05);化疗期间,观察组患者不良反应发生率为8.00%(2/25),明显低于对照组的32.00%(8/25),差异有统计学意义(P<0.05)。结论:华蟾素胶囊联合XELOX方案治疗晚期胃癌的疗效良好,可增强机体免疫功能,减少不良反应。
OBJECTIVE: To probe into the efficacy of Cinobufagin capsule combined with Xelox therapeutic regimen in treatment of advanced gastric cancer and its effect on patients' immunologic function. METHODS: 50 patients with advanced gastric cancer admitted into Jiangxi Dayu County People's Hospital from Jan. 2016 to Feb. 2018 were selected and divided into observation group and control group via random number table, with 25 cases in each group. The control group was given Xelox therapeutic regimen(oxaliplatin combined with capecitabine), while the observation group was treated with Cinobufagin capsule based on the control group. Differences in clinical efficacy, immunologic function and incidences of adverse drug reactions between two groups were compared. RESULTS: The short-term effective rate of observation group was 96.00%(24/25), which was significantly higher than that of the control group(76.00%, 19/25), with statistically significant difference(P<0.05); after treatment, the CD_3~+, CD_4~+, CD_8~+and natural killer cell levels of observation group were significantly higher than those of the control group, with statistically significant differences(P<0.05); during chemotherapy, the incidence of adverse drug reactions the observation group was 8.00%(2/25), which was significantly lower than that of the control group(32.00%, 8/25), with statistically significant difference(P<0.05). CONCLUSIONS: The efficacy of Cinobufagin capsule combined with Xelox therapeutic regimen in treatment of advanced gastric cancer is remarkable, which can reinforce immunity of the organism and reduce the incidence of adverse drug reactions.
OBJECTIVE: To probe into the efficacy of Cinobufagin capsule combined with Xelox therapeutic regimen in treatment of advanced gastric cancer and its effect on patients' immunologic function. METHODS: 50 patients with advanced gastric cancer admitted into Jiangxi Dayu County People's Hospital from Jan. 2016 to Feb. 2018 were selected and divided into observation group and control group via random number table, with 25 cases in each group. The control group was given Xelox therapeutic regimen(oxaliplatin combined with capecitabine), while the observation group was treated with Cinobufagin capsule based on the control group. Differences in clinical efficacy, immunologic function and incidences of adverse drug reactions between two groups were compared. RESULTS: The short-term effective rate of observation group was 96.00%(24/25), which was significantly higher than that of the control group(76.00%, 19/25), with statistically significant difference(P<0.05); after treatment, the CD_3~+, CD_4~+, CD_8~+and natural killer cell levels of observation group were significantly higher than those of the control group, with statistically significant differences(P<0.05); during chemotherapy, the incidence of adverse drug reactions the observation group was 8.00%(2/25), which was significantly lower than that of the control group(32.00%, 8/25), with statistically significant difference(P<0.05). CONCLUSIONS: The efficacy of Cinobufagin capsule combined with Xelox therapeutic regimen in treatment of advanced gastric cancer is remarkable, which can reinforce immunity of the organism and reduce the incidence of adverse drug reactions.
引文
[1] 王芳,柳江,罗健.晚期胃癌化疗及分子靶向治疗研究进展[J].中国医师杂志,2016,18(1):18-21,25.
[2] 尹洪岩,石燕,吴志勇,等.改良DCF与XELOX方案治疗老年晚期胃癌的疗效及安全性分析[J].中国药物应用与监测,2016,13(2):69-73.
[3] 巴一,周礼鲲.晚期胃癌的化疗选择[J].中国肿瘤临床,2016,43(1):21-26.
[4] 徐咏梅,刘声.华蟾素胶囊联合化疗对中晚期胃癌的疗效观察[J].世界中医药,2016,11(7):1212-1214.
[5] Eisenhauer EA,Therasse P,Boqaerts J,et al.New response eva-luation criteria in solid tumours: revised RECIST guideline(version 1.1)[J]. Eur J Cancer,2009,45(2):228-247.
[6] 李金凤,杜伟一,任旭升,等.多西他赛联合XELOX方案治疗晚期胃癌的临床研究[J].解放军医药杂志,2017,29(7):18-21.
[7] 郭仁宏.2013NCCN胃癌临床实践指南(2013.V2)要点介绍及解读[J].中国医学前沿杂志:电子版,2013,5(12):71-78.
[8] 张公正,刘素娜,宋秋岗.消癌平联合XELOX方案对晚期胃癌恶性分子表达的影响[J].安徽医学,2017,38(5):568-571.
[9] 卞伟钢,宋曙,周小宁,等.XELOX方案一线治疗晚期胃癌的临床效果观察[J].实用临床医药杂志,2017,21(21):179-180.
[10] 李烜,李志鹏.晚期胃癌中西医结合临床路径应用研究[J].中医学报,2015,30(2):161-163.
[11] 刘朝敏,姜鹤群,王少龙,等.替吉奥联合华蟾素片治疗老年晚期胃癌的疗效及安全性[J].实用临床医药杂志,2015,19(e01):34-36.
[12] 杨芳,张涛.华蟾素胶囊联合化疗治疗晚期胃癌的临床研究[J].中国药物与临床,2018,18(2):266-268.
[13] 陈静茹.华蟾素胶囊体内外抗肿瘤作用研究[D].咸阳:陕西中医学院,2011:25-27.
[2] 尹洪岩,石燕,吴志勇,等.改良DCF与XELOX方案治疗老年晚期胃癌的疗效及安全性分析[J].中国药物应用与监测,2016,13(2):69-73.
[3] 巴一,周礼鲲.晚期胃癌的化疗选择[J].中国肿瘤临床,2016,43(1):21-26.
[4] 徐咏梅,刘声.华蟾素胶囊联合化疗对中晚期胃癌的疗效观察[J].世界中医药,2016,11(7):1212-1214.
[5] Eisenhauer EA,Therasse P,Boqaerts J,et al.New response eva-luation criteria in solid tumours: revised RECIST guideline(version 1.1)[J]. Eur J Cancer,2009,45(2):228-247.
[6] 李金凤,杜伟一,任旭升,等.多西他赛联合XELOX方案治疗晚期胃癌的临床研究[J].解放军医药杂志,2017,29(7):18-21.
[7] 郭仁宏.2013NCCN胃癌临床实践指南(2013.V2)要点介绍及解读[J].中国医学前沿杂志:电子版,2013,5(12):71-78.
[8] 张公正,刘素娜,宋秋岗.消癌平联合XELOX方案对晚期胃癌恶性分子表达的影响[J].安徽医学,2017,38(5):568-571.
[9] 卞伟钢,宋曙,周小宁,等.XELOX方案一线治疗晚期胃癌的临床效果观察[J].实用临床医药杂志,2017,21(21):179-180.
[10] 李烜,李志鹏.晚期胃癌中西医结合临床路径应用研究[J].中医学报,2015,30(2):161-163.
[11] 刘朝敏,姜鹤群,王少龙,等.替吉奥联合华蟾素片治疗老年晚期胃癌的疗效及安全性[J].实用临床医药杂志,2015,19(e01):34-36.
[12] 杨芳,张涛.华蟾素胶囊联合化疗治疗晚期胃癌的临床研究[J].中国药物与临床,2018,18(2):266-268.
[13] 陈静茹.华蟾素胶囊体内外抗肿瘤作用研究[D].咸阳:陕西中医学院,2011:25-27.